IF you listened to the Infinity webcast at the DB conference the analyst was focused on combo studies and the fact that infi doesn't own a second drug to go along with their PI3K inhibitor.
the reason I find that interesting is because the only company working in the space that owns a combo is TGTX.
pcyc, gilead, roche and abbott, do not have a combo.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.